DexCom, Inc. (DXCM), a San Diego-based medical machine firm with a $32.5 billion market cap, makes a speciality of steady glucose monitoring (CGM) techniques. Its know-how features a small, implantable sensor that tracks glucose ranges beneath the pores and skin and transmits information to an exterior receiver in real-time. DexCom is slated to report its fiscal 2025 second-quarter earnings after the market closes on Wednesday, July 30.
Forward of the occasion, analysts count on DXCM to report a revenue of $0.45 per share on a diluted foundation, up 4.7% from $0.43 per share within the year-ago quarter. The corporate beat the consensus estimates in two of the final 4 quarters whereas lacking the forecast on two different events.
For the total 12 months, analysts count on DXCM to report EPS of $2.03, up 23.8% from $1.64 in fiscal 2024. Its EPS is predicted to rise 24.6% 12 months over 12 months to $2.53 in fiscal 2026.
Over the previous 52 weeks, DXCM’s shares have dipped 25.2%, underperforming the S&P 500’s ($SPX) 13.4% features and the Well being Care Choose Sector SPDR Fund’s (XLV) 5.4% dip over the identical timeframe.
On July 1, DexCom shares fell over 4% after the U.S. authorities proposed adjustments to fee schedules and launched a aggressive bidding program for diabetes units, impacting the broader glucose monitoring and insulin pump sector.
However, analysts’ consensus opinion on DXCM inventory may be very constructive, with an total “Sturdy Purchase” ranking. Out of 25 analysts overlaying the inventory, 20 advise a “Sturdy Purchase” ranking, one suggests a “Reasonable Purchase,” and 4 give a “Maintain.” DXCM’s common analyst value goal is $99.68, indicating a possible upside of 20.2% from the present ranges.
On the date of publication, Kritika Sarmah didn’t have (both straight or not directly) positions in any of the securities talked about on this article. All data and information on this article is solely for informational functions. This text was initially revealed on Barchart.com